182 related articles for article (PubMed ID: 31857702)
1. Deubiquitinating enzyme USP33 restrains docetaxel-induced apoptosis via stabilising the phosphatase DUSP1 in prostate cancer.
Guo F; Zhang C; Wang F; Zhang W; Shi X; Zhu Y; Fang Z; Yang B; Sun Y
Cell Death Differ; 2020 Jun; 27(6):1938-1951. PubMed ID: 31857702
[TBL] [Abstract][Full Text] [Related]
2. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
[TBL] [Abstract][Full Text] [Related]
3. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
[TBL] [Abstract][Full Text] [Related]
4. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
[No Abstract] [Full Text] [Related]
5. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells.
Wang Q; He WY; Zeng YZ; Hossain A; Gou X
Int Urol Nephrol; 2018 Apr; 50(4):675-686. PubMed ID: 29460131
[TBL] [Abstract][Full Text] [Related]
7. Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer.
Miller DR; Tzeng CC; Farmer T; Keller ET; Caplan S; Chen YS; Chen YL; Lin MF
Cancer Lett; 2018 Nov; 436():96-108. PubMed ID: 30077739
[TBL] [Abstract][Full Text] [Related]
8. USP49 inhibits ischemia-reperfusion-induced cell viability suppression and apoptosis in human AC16 cardiomyocytes through DUSP1-JNK1/2 signaling.
Zhang W; Zhang Y; Zhang H; Zhao Q; Liu Z; Xu Y
J Cell Physiol; 2019 May; 234(5):6529-6538. PubMed ID: 30246457
[TBL] [Abstract][Full Text] [Related]
9. DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
Lin YC; Lin YC; Shih JY; Huang WJ; Chao SW; Chang YL; Chen CC
Clin Cancer Res; 2015 Jan; 21(2):428-38. PubMed ID: 25593344
[TBL] [Abstract][Full Text] [Related]
10. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
[TBL] [Abstract][Full Text] [Related]
11. The role of testicular nuclear receptor 4 in chemo-resistance of docetaxel in castration-resistant prostate cancer.
Chen B; Yu S; Ding X; Jing C; Xia L; Wang M; Matro E; Rehman F; Niu Y; Li G; Chang C
Cancer Gene Ther; 2014 Oct; 21(10):411-5. PubMed ID: 25104727
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
[TBL] [Abstract][Full Text] [Related]
13. Zhoushi Qi Ling decoction represses docetaxel resistance and glycolysis of castration-resistant prostate cancer via regulation of SNHG10/miR-1271-5p/TRIM66 axis.
Cao H; Wang D; Sun P; Chen L; Feng Y; Gao R
Aging (Albany NY); 2021 Oct; 13(19):23096-23107. PubMed ID: 34613933
[TBL] [Abstract][Full Text] [Related]
14. DNA polymerase theta repression enhances the docetaxel responsiveness in metastatic castration-resistant prostate cancer.
Kuei CH; Lin HY; Lin MH; Lee HH; Lin CH; Lee WJ; Chen YL; Lu LS; Zheng JQ; Hung RC; Chiu HW; Chen KC; Lin YF
Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165954. PubMed ID: 32877750
[TBL] [Abstract][Full Text] [Related]
15. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
[TBL] [Abstract][Full Text] [Related]
16. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
17. FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy.
Lin JZ; Wang WW; Hu TT; Zhu GY; Li LN; Zhang CY; Xu Z; Yu HB; Wu HF; Zhu JG
Cancer Lett; 2020 Jan; 469():481-489. PubMed ID: 31738958
[TBL] [Abstract][Full Text] [Related]
18. Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.
Kang Y; Nagaraja AS; Armaiz-Pena GN; Dorniak PL; Hu W; Rupaimoole R; Liu T; Gharpure KM; Previs RA; Hansen JM; Rodriguez-Aguayo C; Ivan C; Ram P; Sehgal V; Lopez-Berestein G; Lutgendorf SK; Cole SW; Sood AK
Clin Cancer Res; 2016 Apr; 22(7):1713-24. PubMed ID: 26581245
[TBL] [Abstract][Full Text] [Related]
19. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
[TBL] [Abstract][Full Text] [Related]
20. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
[Next] [New Search]